257 related articles for article (PubMed ID: 26573802)
1. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.
Shi XB; Ma AH; Xue L; Li M; Nguyen HG; Yang JC; Tepper CG; Gandour-Edwards R; Evans CP; Kung HJ; deVere White RW
Cancer Res; 2015 Dec; 75(24):5309-17. PubMed ID: 26573802
[TBL] [Abstract][Full Text] [Related]
2. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
4. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
[TBL] [Abstract][Full Text] [Related]
5. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
6. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
[TBL] [Abstract][Full Text] [Related]
7. Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.
Liu YN; Yin J; Barrett B; Sheppard-Tillman H; Li D; Casey OM; Fang L; Hynes PG; Ameri AH; Kelly K
Mol Cell Biol; 2015 Jun; 35(11):1940-51. PubMed ID: 25802280
[TBL] [Abstract][Full Text] [Related]
8. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
9. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma.
Boll K; Reiche K; Kasack K; Mörbt N; Kretzschmar AK; Tomm JM; Verhaegh G; Schalken J; von Bergen M; Horn F; Hackermüller J
Oncogene; 2013 Jan; 32(3):277-85. PubMed ID: 22391564
[TBL] [Abstract][Full Text] [Related]
10. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.
Lin PC; Chiu YL; Banerjee S; Park K; Mosquera JM; Giannopoulou E; Alves P; Tewari AK; Gerstein MB; Beltran H; Melnick AM; Elemento O; Demichelis F; Rubin MA
Cancer Res; 2013 Feb; 73(3):1232-44. PubMed ID: 23233736
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
[TBL] [Abstract][Full Text] [Related]
13. miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
Larne O; Hagman Z; Lilja H; Bjartell A; Edsjö A; Ceder Y
Carcinogenesis; 2015 Aug; 36(8):858-66. PubMed ID: 25969144
[TBL] [Abstract][Full Text] [Related]
14. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
Östling P; Leivonen SK; Aakula A; Kohonen P; Mäkelä R; Hagman Z; Edsjö A; Kangaspeska S; Edgren H; Nicorici D; Bjartell A; Ceder Y; Perälä M; Kallioniemi O
Cancer Res; 2011 Mar; 71(5):1956-67. PubMed ID: 21343391
[TBL] [Abstract][Full Text] [Related]
15. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
16. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
18. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
19. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor regulates SRC expression through microRNA-203.
Siu MK; Chen WY; Tsai HY; Yeh HL; Yin JJ; Liu SY; Liu YN
Oncotarget; 2016 May; 7(18):25726-41. PubMed ID: 27028864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
